alpha-MSH analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-05. Anything still debated is marked as such rather than presented as settled.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Now differences between the contemporary squid and octopus samples became very clear. In the octopus, broad bands of fibers passed across the plane of the tissue and were separated by equally broad bands arranged in a perpendicular direction. In the squid there were narrower but also relatively broad bundles arranged in the plane of the section, separated by thin partitions of perpendicular fibers. It seemed I had found a means to identify the mystery sample after all. I could distinguish between octopus and squid, and between them and mammals, which display a lacy network of connective tissue fibers. After 75 years, the moment of truth was at hand. Viewing section after section of the St. Augustine samples, we decided at once, and beyond any doubt, that the sample was not whale blubber. Further, the connective tissue pattern was that of broad bands in the plane of the section with equally broad bands arranged perpendicularly, a structure similar to, if not identical with, that in my octopus sample. The evidence appears unmistakable that the St. Augustine sea monster was in fact an octopus, but the implications are fantastic. Even though the sea presents us from time to time with strange and astonishing phenomena, the idea of a gigantic octopus, with arms 75 to 100 feet in length and about 18 inches in diameter at the base—a total spread of some 200 feet—is difficult to comprehend.
The IRP was created in 2000 as ENCI (Estructura No Convencional de Investigación – Unconventional Research Structure) according to the UPV government committee of 21 December 1999. Later, according to the Spanish Order 6/2006, of 13 January, of the local government (Generalitat Valenciana) (DOGV-núm. 5179 of 18 January 2006), the IRP was appointed as Research University Institute of the Universitat Politècnica de València.
He also played a significant role in the winning elimination final against Western Bulldogs, but an injury sustained in the game ended his season. It was announced in early March 2021 that Ryder would temporarily step away from the club to spend time with his family and elders. Ryder received the full support of the club. Ryder returned to the club in April and played his first game for the season in the round seven win over Hawthorn in which he gathered five tackles, three clearances and 36 hitouts (significantly above the AFL average). Ryder had a purple patch in rounds 10-12, collecting 41, 34 and 34 hitouts in three games. Ryder also had a solid game in round 16 against Collingwood and champion Brodie Grundy, collecting 23 hitouts and kicking two goals. Ryder's last game for 2021 was Round 19, after which he battled an achilles injury which saw him miss the remainder of the season. After playing 12 of a possible 22 games and averaging over 30 hitouts a game, Ryder re-signed with the Saints for another season. After another injury-interrupted year for St Kilda during the side's 2022 season, Ryder announced his retirement on 20 August, ending a career of 281 games across three clubs.
Sources: en.wikipedia.org
=== Other === Deformity type Erlenmeyer flask gives a distal femur similar to an Erlenmeyer flask. It may result from Gaucher disease. Kashin–Beck disease Melnick–Needles syndrome Ovine chondrodysplasia Familial osteodysplasia, Anderson type Ulna metaphyseal dysplasia syndrome
Collagen alpha-1(XIX) chain is a protein that in humans is encoded by the COL19A1 gene. This gene encodes the alpha chain of type XIX collagen, a member of the FACIT collagen family (fibril-associated collagens with interrupted helices). Although the function of this collagen is not known, other members of this collagen family are found in association with fibril-forming collagens such as type I and II, and serve to maintain the integrity of the extracellular matrix. The transcript produced from this gene has an unusually large 3' UTR which has not been completely sequenced.
==== Compound collagen scaffolds ==== Compound collagen-based scaffolds have been developed in an attempt to improve the function of these scaffolds for tissue engineering. An example of a compound collagen scaffold is the collagen-chitosan matrix. Chitosan is a polysaccharide that is chemically similar to cellulose. Unlike collagen, chitosan biodegrades relatively slowly. However, chitosan is not very biocompatible with fibroblasts. To improve the stability of scaffolds containing gelatin or collagen and the biocompatibility of chitosan is made by crosslinking the two; they compensate for each other's shortcomings. Collagen-elastine membrane, collagen-glycosaminoglycane (C-GAG) matrix, cross-linked collagen matrix Integra and Terudermis are other examples of compound collagen scaffolds. Allogeneic cultured keratinocytes and fibroblasts in bovine collagen (Gintuit) is the first cell-based product made from allogeneic human cells and bovine collagen approved by the US Food and Drug Administration (FDA). It is an allogeneic cellularized scaffold product and was approved for medical use in the United States in March 2012.
Sources: en.wikipedia.org
Several aircraft and helicopters were damaged in a storm on 1 July 2017 that struck the air force's main base at N'Djamena International Airport. The severity of the storm was amplified by the use of fabric hangar coverings. Losses or damaged equipment included three helicopters, a PC-12, a MiG-29 fighter, and two Su-25 attack planes. The force shared a base with French forces at N'Djamena International Airport until January 2025 when the French withdrew.
火 (huǒ, fire) e.g.: 烷 (wán, alkane), common for hydrocarbons 酉 (yǒu, ritual wine vessel) e.g.: 酮 (tóng, ketone), common for oxygenated functionalities 艸 (cǎo, grass) e.g. 苯 (běn, benzene, phenyl), common for aromatic compounds and terpenes 肉 (ròu, meat, flesh) e.g. 腙 (zōng, hydrazone), common for nitrogen-containing functionalities Additionally, the mouth radical (口, kǒu) is affixed to characters that are used for their sound only. This occurs often in the transliteration of the names of heterocyclic compounds, (e.g., 吡啶, "bǐdìng", pyridine). These characters are also used for the transliteration of non-chemical terms from foreign languages.
In 1992, the Moscow government began planning a new area in central Moscow—the Moscow International Business Center—to create a zone, the first in Russia and Eastern Europe, to combine business activity, living space, and entertainment. Situated in the Presnensky District and located at the Third Ring, the Moscow City area is undergoing intensive development. The Moscow International Business Center (MIBC) is being constructed on the Krasnopresnenskaya embankment. The project occupies up to one square kilometer (250 acres). That area is the only location in downtown Moscow able to accommodate a project of such size. Most pre-existing buildings in that area are old factories and industrial complexes. Demonstrating the MIBC's scale, the Federation Tower, completed in 2016, is the second-tallest building in Europe. The project's broader plans include a water park and other recreational facilities; business, office, entertainment, and residential buildings; a transport network; and a new site for the Moscow government. Four new metro stations in the area have been built; two of these have opened, and two others are reserved for future metro lines crossing the MIBC. Additional stations were planned. In addition, a rail shuttle service is planned to directly connect the MIBC with the Sheremetyevo International Airport. Major thoroughfares through the MIBC are the Third Ring and Kutuzovsky Prospekt. Three metro stations were initially planned for the Filyovskaya Line. The Delovoi Tsentr station opened in 2005 and was renamed Vystavochnaya in 2009.
== Role in detoxification of xenobiotic substances == One of the primary roles of bacterial glutathione transferases is to reduce the toxic effects of xenobiotics from the cell using the phase II system of detoxification metabolism. Xenobiotics are compounds foreign to the bacterium's natural biochemistry, and phase II of their detoxification involves conjugating them to polar, soluble compounds that can be safely excreted from the cell. GSTs are essential in this process because they catalyze the nucleophilic attack of glutathione on various electrophilic residues of xenobiotic substrates, thereby preventing their disruption of vital cellular proteins and nucleic acids. Similar to the mechanism GSTs use for catalyzation of redox reactions, the mechanism for detoxification first involves the binding of two substrates to the enzyme. A GST monomer binds a glutathione molecule to its N-terminal glutathione-binding site. On the adjacent hydrophobic alpha-helical binding site on the C-terminal domain, the GST binds a hydrophobic xenobiotic molecule. Formation of the active site recruits another GST monomer to interact with the system and the enzymes dimerize. The active GST complex catalyzes the -SH residue on glutathione to perform a nucleophilic attack on electrophilic carbon, sulfur, or nitrogen atoms of the xenobiotic substrate. The conjugation of glutathione on the previously hydrophobic-toxic substrate results in a soluble compound, which is more readily exocytosed by the cell.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.